Literature DB >> 7698180

Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier.

C Héron1, J Costentin, J J Bonnet.   

Abstract

We have studied the ability of various uptake blockers to protect the dopamine neuronal carrier labeled with [3H]GBR 12783 (1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-(propenyl)-piperazine) against N-ethylmaleimide-induced alkylation, using membrane preparations obtained from rat striatum. Pure uptake inhibitors such as mazindol, pyrovalerone, nomifensine and methylphenidate, and substrates (dopamine, d-amphetamine, m-tyramine) protected the [3H]GBR 12783 binding site in a concentration-dependent manner. Preincubation of the membranes with these agents prior to N-ethylmaleimide treatment did not modify the protecting ability of substrates, whereas it significantly improved that of pure uptake inhibitors including cocaine. When the preincubation was omitted, the concentration dependence of the protection observed with pure uptake inhibitors decreased and a maximal 40% protection was observed for 10 microM to 1 mM cocaine concentrations. Effective protecting concentrations of blockers are correlated with their Ki determined in standard binding studies. These results reveal that all pure uptake inhibitors bind slowly to the dopamine neuronal carrier whereas substrates interact with it rapidly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698180     DOI: 10.1016/0014-2999(94)00502-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  The role of peripheral and central sodium channels in mediating brain temperature fluctuations induced by intravenous cocaine.

Authors:  Eugene A Kiyatkin; P Leon Brown
Journal:  Brain Res       Date:  2006-09-07       Impact factor: 3.252

2.  Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter.

Authors:  M E Reith; C Xu; L Zhang; L L Coffey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 3.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

4.  Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

Authors:  Richard H Weisler; Ann C Childress
Journal:  Prim Care Companion CNS Disord       Date:  2011

5.  Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics.

Authors:  Thomas E Wooters; Michael T Bardo; Linda P Dwoskin; Narasimha M Midde; Adrian M Gomez; Charles F Mactutus; Rosemarie M Booze; Jun Zhu
Journal:  Behav Brain Res       Date:  2011-01-08       Impact factor: 3.332

6.  Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Authors:  Michael H Baumann; John S Partilla; Kurt R Lehner; Eric B Thorndike; Alexander F Hoffman; Marion Holy; Richard B Rothman; Steven R Goldberg; Carl R Lupica; Harald H Sitte; Simon D Brandt; Srihari R Tella; Nicholas V Cozzi; Charles W Schindler
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

7.  Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice.

Authors:  Andrew J Mcgeehan; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

8.  In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Authors:  William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

Review 9.  Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

Authors:  J Zhu; M E A Reith
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

10.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.